Christopher Ryan Schadel bought $3,920 of ZSQR
Chief Marketing Officer at Coeptis Therapeutics Holdings, Inc.. 1,000 shares at an average of $3.92, traded Aug 18, 2026, filed Aug 20, 2026.
Score components
- +15RoleOfficer
- 0Trade size$4k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +18Price context0% above the 52-week low; 80% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001185185-26-003631, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | POpen-market purchase Common Stock | +1,000 | $3.92 | $3,920 | 1,000 | Aug 20, 2026 |
| Jun 3, 2026 | AGrant or award Restricted Stock Unitsderivative | +2,806 | $0.00 | $0 | 12,674 | Aug 20, 2026 |
| Apr 27, 2026 | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Aug 20, 2026 |
| Apr 27, 2026 | AGrant or award Restricted Stock Unitsderivative | +9,868 | $0.00 | $0 | 9,868 | Aug 20, 2026 |
Related signals
Other insiders at Coeptis Therapeutics Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | ZSQRbuy Coeptis Therapeutics Holdings, Inc. | Christopher Ryan Schadel Chief Marketing Officer | $3,920 1,000 shares | +41% | |
| 61Notable | Coeptis Therapeutics Holdings, Inc. | Brian Cogley Chief Financial Officer | $3,350 5,000 shares | +20% | |
| 51Moderate | Coeptis Therapeutics Holdings, Inc. | Tara DeSilva director | $1,305 2,266 shares | +8% | |
| 54Moderate | Coeptis Therapeutics Holdings, Inc. | Christopher P. Cochran director | $5,390 7,000 shares | +23% | |
| 53Moderate | Coeptis Therapeutics Holdings, Inc. | David Mehalick CEO and President | $17k 25,054 shares | +1% | |
| 43Moderate | Coeptis Therapeutics Holdings, Inc. | Gene Salkind director | $8,004 11,600 shares | +4% | |
| 48Moderate | Coeptis Therapeutics Holdings, Inc. | Daniel Alexander Yerace VP of Operations | $7,487 10,850 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.